Editas Medicine, Inc. (EDIT)
2.17
+0.03
(+1.40%)
USD |
NASDAQ |
Nov 13, 16:00
2.165
0.00 (0.00%)
After-Hours: 19:59
Editas Medicine Price : 2.17 for Nov. 13, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | 2.14 | 2.21 | 2.01 | 2.17 | 2.792M |
| Nov 12, 2026 | 2.33 | 2.33 | 2.12 | 2.14 | 3.887M |
| Nov 11, 2026 | 2.51 | 2.52 | 2.36 | 2.38 | 1.980M |
| Nov 10, 2026 | 2.70 | 2.750 | 2.475 | 2.505 | 1.590M |
| Nov 09, 2026 | 2.64 | 3.005 | 2.511 | 2.75 | 3.722M |
| Nov 06, 2026 | 2.55 | 2.63 | 2.475 | 2.57 | 1.717M |
| Nov 05, 2026 | 2.68 | 2.68 | 2.41 | 2.55 | 2.099M |
| Nov 04, 2026 | 2.70 | 2.79 | 2.61 | 2.72 | 2.369M |
| Nov 03, 2026 | 2.61 | 2.71 | 2.57 | 2.60 | 1.757M |
| Nov 02, 2026 | 2.71 | 2.778 | 2.55 | 2.57 | 1.237M |
| Oct 30, 2026 | 2.89 | 2.92 | 2.60 | 2.67 | 2.909M |
| Oct 29, 2026 | 2.945 | 2.98 | 2.86 | 2.93 | 3.227M |
| Oct 28, 2026 | 2.59 | 2.96 | 2.54 | 2.95 | 4.430M |
| Oct 27, 2026 | 2.41 | 2.61 | 2.37 | 2.60 | 3.079M |
| Oct 26, 2026 | 2.39 | 2.445 | 2.36 | 2.40 | 1.351M |
| Oct 23, 2026 | 2.44 | 2.45 | 2.30 | 2.40 | 1.314M |
| Oct 22, 2026 | 2.47 | 2.58 | 2.45 | 2.49 | 1.066M |
| Oct 21, 2026 | 2.59 | 2.60 | 2.50 | 2.51 | 1.139M |
| Oct 20, 2026 | 2.40 | 2.665 | 2.35 | 2.58 | 2.266M |
| Oct 19, 2026 | 2.38 | 2.43 | 2.27 | 2.42 | 2.011M |
| Oct 16, 2026 | 2.44 | 2.47 | 2.33 | 2.35 | 1.552M |
| Oct 15, 2026 | 2.26 | 2.465 | 2.25 | 2.44 | 1.860M |
| Oct 14, 2026 | 2.44 | 2.475 | 2.245 | 2.27 | 2.829M |
| Oct 13, 2026 | 2.73 | 2.73 | 2.44 | 2.445 | 2.454M |
| Oct 12, 2026 | 2.90 | 2.91 | 2.73 | 2.75 | 1.297M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Alnylam Pharmaceuticals, Inc. | 165.04 |
| Vertex Pharmaceuticals, Inc. | 538.60 |
| Recursion Pharmaceuticals, Inc. | 3.185 |
| Halozyme Therapeutics, Inc. | 100.27 |
| Novavax, Inc. | 8.525 |
Price Related Metrics
| PS Ratio | 5.096 |
| Price to Book Value | 3.945 |
| Earnings Yield | -28.48% |
| Market Cap | 333.44M |